Dan Dan Xu

Prof. Dr. Dan Dan Xu

Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2022 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
Muhammad Danish YaqoobMuhammad Danish Yaqoob
Muhammad Danish Yaqoob
LXLong Xu
Long Xu
CLChuanfeng Li
Chuanfeng Li
MLMerrin Man Long Leong
Merrin Man Long Leong
DXDan Dan Xu
Dan Dan Xu

1 October 2008 in Laser Physics Letters
Verified
Journal Article
Closed access
PDF file
YTY.Y. Tian
Y.Y. Tian
DXDan Dan Xu
Dan Dan Xu
XTX. Tian
X. Tian
FCF.A. Cui
F.A. Cui
HYHuiqing Yuan
Huiqing Yuan
WLW.N. Leung
W.N. Leung

1 January 2014 in The American Journal of Chinese Medicine
Verified
Journal Article
Closed access
MYMengmeng Yang
Mengmeng Yang
DXDan Dan Xu
Dan Dan Xu
YZYan Zhang
Yan Zhang
XLXinyou Liu
Xinyou Liu
RHRobin Hoeven
Robin Hoeven
William C. ChoWilliam C. Cho
William C. Cho

1 September 2013 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
DXDan Dan Xu
Dan Dan Xu
Hon-Ming LamHon-Ming Lam
Hon-Ming Lam
RHRobin Hoeven
Robin Hoeven
CXChong Bing Xu
Chong Bing Xu
ALAlbert Wing Nang Leung
Albert Wing Nang Leung
WCWilliam Chi Shing Cho
William Chi Shing Cho

1 July 2010 in European Journal of Pharmacology
Verified
Journal Article
Closed access
HLHaitao Li
Haitao Li
WWWilliam Wu
William Wu
ZZZong-Ping Zheng
Zong-Ping Zheng
CCChun Tao Che
Chun Tao Che
ZLZhi Jie Li
Zhi Jie Li
Mingfu WangMingfu Wang
Mingfu Wang

15 July 2021 in Molecular Medicine Reports
Verified
Journal Article
Open access
PDF file
DXDan Dan Xu
Dan Dan Xu
PYPing Yang
Ping Yang
ZYZhang-Jian Yang
Zhang-Jian Yang
QLQiu-Gen Li
Qiu-Gen Li
YOYe-Tong Ouyang
Ye-Tong Ouyang
XHXiao-Jian Han
Xiao-Jian Han
Alzheimer's disease (AD), one of the most common types of chronic neurodegenerative diseases, is pathologically characterized by the formation of amyloid β (Aβ) peptide‑containing plaques and neurofibrillary tangles. Among Aβ peptides, Aβ1‑42 induces neuronal toxicity and neurodegeneration. In our previous studies, Cdk5 was found to regulate Aβ1‑42‑induced mitochondrial fission via the phosphorylation of dynamin‑related protein 1 (Drp1) at Ser579. However, whether blockage of Drp1 phosphorylation at Ser579 protects neurons against Aβ1‑42‑induced degeneration remains to be elucidated. Thus, the aim the present study was to examine the effect of mutant Drp1‑S579A on neurodegeneration and its underlying mechanism. First, the phosphorylation‑defect (phospho‑defect) mutant, Lenti‑Drp1‑S579A was constructed. Phospho‑defect Drp1‑S579A expression was detected in primary cultures of mouse cortical neurons infected with Lenti‑Drp1‑S579A using western blotting and it was found to successfully attenuate the phosphorylation of endogenous Drp1 at Ser579. In primary neuronal cultures, the neuronal processes were evaluated under microscopy. Treatment with 10 µM Aβ1‑42 significantly decreased dendritic density and length, spine outgrowth and synapse number. As expected, infection of neurons with Lenti‑Drp1‑S579A efficiently alleviated the inhibitory effect of Aβ1‑42 on neurite outgrowth and synapse density. In addition, infection with Lenti‑Drp1‑S579A abolished the cleavage of caspase‑3 and apoptosis in neurons exposed to Aβ1‑42. Thus, the current data demonstrated that blockage of Drp1 phosphorylation at Ser579 may be an effective strategy to protect neurons against Aβ1‑42‑induced degeneration and apoptosis. These findings underline the therapeutic potential of targeting Drp1 in the treatment of AD.